Risk of suicide in depression and its implication for psychopharmacological treatment

International Clinical Psychopharmacology

Volumn 11, Issue 2, 1996, Pages 71-79

  Kasper, S ^a   Schindler, S ^a   Neumeister, A ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antidepressants; Depression; Overdosage; Selective serotonin reuptake inhibitors (SSRIs); Self poisoning; Suicide

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; DIBENZEPIN; DOSULEPIN; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; IPRINDOLE; IPRONIAZID; LOFEPRAMINE; MAPROTILINE; MELITRACEN; MIANSERIN; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; OPIPRAMOL; PAROXETINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VILOXAZINE;

DEPRESSION; DRUG INTOXICATION; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SELF POISONING; SUICIDAL BEHAVIOR; SUICIDE;

EID: 0029889650     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199611020-00001     Document Type: Review

References (96)

1. Arango V, Underwood MD and Mann JJ (1992) Alterations in monoamine receptors in the brain of suicide victims. Journal of Clinical Psychopharmacology, 12, 8S-12S.
2. Åsberg M, Nordström P and Träskman-Bendz L (1986) Cerebrospinal fluid studies in suicide. An overview. Annals of the New York Academy of Science, 487, 243-255.
3. Babigian MM and Guttmacher LB (1984) Epidemiological considerations in electroconclusive therapy. Archives of General Psychiatry, 41, 246-253.
4. Barraclough B (1972) Suicide prevention, recurrent affective disorders and lithium. British Journal of Psychiatry, 121, 391-392.
5. Barraclough B, Bunch J and Nelson B (1974) A hundred cases of suicide: clinical aspects. British Journal of Psychiatry, 125, 355-373.
6. Beasley CM, Dornseif BE, Bosomworth JC, Sayler ME and Rampey AH (1991) Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. British Medical Journal, 303, 685-692.
7. Beaumont G and Hetzel W (1992) Patients at risk of suicide and overdose. Psychopharmacology, 106, S123-S126.
8. Blumenthal SJ (1988) Suicide: a guide to risk factors, assessment and treatment of suicidal patients. Medical Clinics of North America, 72, 937-962.
9. Brinkley R, Beitman BD and Friedel RO (1979) Low-dose neuroleptic regimen in the treatment of borderline patients. Archives of General Psychiatry, 36, 319-326.
10. Bulusu I and Alderson M (1984) Suicides 1950-1982. Office of population censuses and survey HMSO, London. Population Trends, 35, 11-13.
11. Cassidy S and Henry J (1987) Fatal toxicity of antidepressant drugs in overdose. British Medical Journal, 295, 1021-1024.
12. Causemann B and Muller-Oerlinghausen B (1988) Does lithium prevent suicides and suicide attempts? In: Lithium: Organic Pharmacology and Psychiatric Use (Ed. NY Birch), pp. 23-24. IRL Press, Oxford.
13. Coccaro EF, Siever LJ, Klar HM, et al. (1989) Serotenergic studies in patients with effective and personality disorders. Archives of General Psychiatry, 46, 587-599.
14. Coppen A, Standish-Barry H, Bailey J, Houston G, Silcocks P and Hermon C (1990) Long-term lithium and mortality. Lancet, 335, 1347.
15. Cowdry RW and Gardner DL (1988) Pharmacotherapy for borderline personality disorder. Archives of General Psychiatry, 45, 111-119.
16. Crow TJ, Cross AJ, Cooper SJ, et al. (1984) Neurotransmitter receptors and monoamine metabolities in the brains of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology, 23, 1561-1569.
17. Damluji NF and Ferguson JM (1988) Paradoxical worsening of depressive symptomatology caused by antidepressant. Journal of Clinical Psychopharmacology, 8, 347-349.
18. De Jonghe F and Swinkels JA (1992) The safety of antidepressants. Drugs, 43 (Suppl 2), 40-47.
19. De Wilde J, Mertens C, Fredricson Overo K, et al. (1985) Citalopram versus mianserin. Acta Psychiatricia Scandinavica, 72, 89-96.
20. Durkheim E (1951) Suicide (translators JA Spaulding and G Simpson). Free Press, New York.
21. Fava M and Rosenbaum JF (1991) Suicidality and fluoxetine: is there a relationship? Journal of Clinical Psychiatry, 52, 108-111.
22. Fink M (1987) Convulsive therapy in affective disorders: a decade of understanding and acceptance. In: Psychopharmacology: The Third Generation of Progress (Ed. HY Meltzer), pp. 1071-1076. Raven Press, New York.
23. Gaind R and Jacobi R (1978) Benzodiazepines causing aggression. In: Current Themes in Psychiatry (Eds R Gaind and BL Hudson), pp. 371-379. London Publishing Company.
24. Gardner DL and Cowdry RW (1985) Alprazolam-induced dyscontrol in borderline personality disorder. American Journal of Psychiatry, 142, 98-100.
25. Gaszner P (1989) Fluvoxamine therapy for depressed patients. In: Psychiatry Today: VIII World Congress of Psychiatry Abstracts (Eds CN Stefanis, CR Soldatos and AD Rabavilas), p. 55. Elsevier, New York.
26. Gonella G, Baignoli G and Ecari V (1990) Fluvoxamine and imipramine in the treatment of depressive patients: a double-blind controlled study. Current Medical Research Opinion, 12, 177-184.
27. Goodman-Gilman et al. (1990) The Pharmacological Basis of Therapeutics, 8th edn., p. 412. Pergamon Press, New York.
28. Gross-Isseroff R, Israeli M and Biegon A (1989) Autoradiographic analysis of tritiated imipramine binding in the human brain post mortem: effects of suicide. Archives of General Psychiatry, 46, 237-241.
29. Guze SB and Robins E (1970) Suicide among primary affective disorders. British Journal of Psychiatry, 117, 437-438.
30. Hagnell O, Lanke J and Rorsman B (1981) Suicide rates in the Lundby study; mental illness as a risk factor for suicide. Neuropsychology, 7, 248-253.
31. Hendin H (1991) Psychodynamics of suicide, with particular reference to the young. American Journal of Psychiatry, 148, 1150-1157.
32. Henry JA (1989) A fatal toxicity index for antidepressant poisoning. Acta Psychiatrica Scandinavica, 80, 37-45.
33. Henry JA, Alexander CA and Sener EK (1995) Relative mortality from overdose of antidepressants. British Medical Journal, 310, 221-224.
34. Kapur S, Mieczkowski T and Mann JJ (1992) Antidepressant medications and the relative risk of suicide attempt and suicide. Journal of the American Medical Association, 268, 3441-3445.
35. Kasper S (1993) Is severe depression a different illness? The pharmacological evidence. European Neuropsychopharmacology, 3, 215-217.
36. Kasper S, Voll G, Vieira A and Kick H (1990) Response to total sleep deprivation before and during treatment with fluvoxamine of maprotiline in patients with major depression - results of a double-blind study. Pharmacopsychiatry, 23, 135-142.
37. Kasper S, Fuger J and Möller HJ (1992) Comparative efficacy of antidepressants. Drugs, 43 (Suppl 2), 11-23.
38. Kasper S, Höflich G, Scholl HP and Möller HJ (1994) Safety and antidepressant efficacy of selective serotonin re-uptake inhibitors. Human Psychopharmacology, 9, 1-12.
39. Kasper S, Lepine J-P, Mendlewicz J, Montgomery S-A and Rush A-J (1994/1995) Efficacy, safety and indications for tricyclic and newer antidepressants. Depression, 2, 127-137.
40. Kasper S, Möller H-J, Montgomery S and Zondag E (1995) Antidepressant efficacy in relation to item analysis and severity of depression: a placebo-controlled trial of fluvoxamine versus imipramine. International Journal of Psychopharmacology, 9 (Suppl 4), 3-12.
41. 2 receptor studies. Neuropsychopharmacology, 3, 361-369.
42. Mann JJ and Arango V (1992) Integration of neurobiology and psychopathology in a unified model of suicidal behavior. Journal of Clinical Psychopharmacology, 12, 2S-7S.
43. Mann JJ, McBride PA and Stanley M (1986a) Postmortem monoamine receptor and enzyme studies in suicide. Annals of the New York Academy of Science, 487, 114-121.
44. 2 and β-adrenergic receptor binding in the frontal cortices of suicide victims. Archives of General Psychiatry, 43, 954-959.
45. Mann JJ, Arango V, Marzuk PM, Theccanat S and Reis DJ (1989) Evidence for the 5-HT hypothesis of suicide: a review of post-mortem studies. British Journal of Psychiatrym 155 (Suppl), 7-14.
46. McBride PA, Tierney H, DeMeo M, Chen J-S and Mann JJ (1990) Effects of age and gender on CNS serotonergic responsivity in normal adults. Biological Psychiatry, 27, 1143-1155.
47. Meyerson LR, Wennogle LP, Abel MS, et al. (1982) Human brain receptor alterations in suicide victims. Pharmacological and Biochemical Behaviour, 17, 159-163.
48. Miles D (1977) Conditions predisposing to suicide: a review. Journal of Nervous and Mental Diseases, 164, 231-246.
49. Miller R and Chabrier LA (1987) The relation of delusional content in psychotic depression to life threatening behavior. Suicide and Life Threatening Behaviour, 17, 13-17.
50. Minkoff K, Bergmann E and Beck A (1973) Hopelessness, depression and attempted suicide. American Journal of Psychiatry, 130, 455-459.
51. Modestin J and Schwarzenbach F (1992) Effect of psychopharmacotherapy on suicide risk in discharged psychiatric inpatients. Acta Psychiatrica Scandinavica, 85, 173-175.
52. Möller HJ (1992) Antidepressants - do they decrease or increase suicidality? Pharmacopsychiatry, 25, 249-253.
53. Möller H-J and Steinmeyer EM (1994) Are serotonergic reuptake inhibitors more potent in reducing suicidality? An empirical study on paroxetine. European Neuropsychopharmacology, 4, 55-59.
54. Möller HJ, Berzewski H, Gonzales N, et al. (1993) A double-blind, multicentre study of paroxetine and amitriptyline in depressed inpatients. Pharmacopsychiatry, 26, 75-78.
55. Möller H-J, Fuger J and Kasper S (1994) Efficacy of new generation antidepressants: meta-analysis of imipramine controlled studies. Pharmacopsychiatry, 27, 215-223.
56. Montgomery SA (1989) The efficacy of fluoxetine as an antidepressant in the short and long term. International Clinical Psychopharmacology, 4 (Suppl 1), 113-119.
57. Montgomery SA (1992) Suicide and antidepressants. Drugs, 43 (Suppl 2), 24-31.
58. Montgomery SA (1993) Suicide prevention and serotonergic drugs. International Clinical Psychopharmacology, 8 (Suppl 2), 83-85.
59. Montgomery SA and Montgomery DB (1982) Pharmacological prevention of suicidal behaviour. Journal of Affective Disorders, 4, 291-298.
60. Montgomery SA and Montgomery DB (1984) The prevention of suicidal acts in high risk patients. In: Frontiers in the Biochemical and Pharmacological Research in Depression (Ed. E. Usdin), pp. 315-317. Raven Press, New York.
61. Montgomery SA and Pinder RM (1987) Do some antidepressants promote suicide? Psychopharmacology, 92, 265-266.
62. Montgomery SA, Montgomery SB, Rani SJ, et al. (1979) Maintenance therapy in repeat suicidal behaviour: a placebo-controlled trial. Proceedings of the 10th International Congess for Suicide Prevention and Crisis Intervention, pp. 227-229, Ottawa.
63. Montgomery SA, McAuley R, Rani SJ, Roy D and Montgomery D (1981) A double-blind comparison of zimelidine and amitriptyline in endogenous depression. Acta Psychiatrica Scandinavica, 63 (Suppl 290), 314-327.
64. Montgomery SA, Lambert MT and Lynch SPJ (1988) The risk of suicide with antidepressants. International Clinical Psychopharmacology, 3 (Suppl 2), 15-24.
65. Montgomery SA, Montgomery DB, Green M, Bullock T and Baldwin D (1992) Pharmacotherapy in the prevention of suicidal behavior. Journal of Clinical Psychopharmacology, 12, 27S-31S.
66. Montgomery SA, Dunner DL and Dunbar GC (1995) Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. European Neuropsychopharmacology, 5, 5-13.
67. Muijen M, Roy D, Silverstone T, et al. (1988) A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients. Acta Psychiatrica Scandinavica, 78, 384-390.
68. Müller-Oerlinghausen B, Kossmann B, Volks J, et al. (1988) Frequency, quality and temporal pattern of relapses during ten years of lithium prophylaxis. In: Lithium: Inorganic Pharmacology and Psychiatric Use (Ed. NY Birch), pp. 145-146, IRL Press, Oxford.
69. Mullin JM, Pandita-Gunawardena VR and Whitehead AM (1988) A double-blind comparison of fluvoxamine and dothiepin in the treatment of major affective disorder. British Journal of Clinical Practice, 42, 51-55.
70. Murphy DL, Mueller EA, Garrick NA and Aulakh CS (1986) Use of serotonergic agents in the clinical assessment of central serotonin function. Journal of Clinical Psychiatry, 41, 9S-15S.
71. Murphy GE (1986) The physician's role in suicide prevention. In: Suicide (Ed. A. Roy), pp. 171-179. Williams & Wilkins, Baltimore.
72. Ottevanger EA (1993) Fluvoxamine superior to imipramine in suicidal depressed patients. European Neuropsychopharmacology, 3, 362-363.
73. Owen F, Chambers DR, Cooper SJ, et al. (1986) Serotonergic mechanisms in brains of suicide victims. Brain Research, 362, 185-188.
74. Paul SM, Rehavi M, Skolnick P and Goodwin FK (1984) High affinity binding of antidepressants to a biogenic amine transport site in human brain and platelet; studies in depression. In: Neurobiology of Mood Disorders (Eds RM Post and CJ Bellinger), pp. 845-853. Williams & Wilkins, Baltimore.
75. Pokorny AD (1964) Suicide rates in various psychiatric disorders. Journal of Nervous and Mental Diseases, 139, 499-506.
76. Robins LN and Kulbok PA (1986) Methodological strategies in suicide. Annals of the New York Academy of Sciences, 487, 1-15.
77. Robinson DS and Kurtz NM (1987) Monoamine oxidase inhibiting drugs: pharmacologic and therapeutic issues. In: Psychopharmacology: The Third Generation of Progress (Ed. HY Meltzer), pp. 1297-1304. Raven Press, New York.
78. Rouillon F, Phillips R, Serrurier E, Ansart E and Gerard MJ (1989) Prophylactic efficacy of maprotiline on relapses of unipolar depression. L'Encephale, 15, 527-534.
79. Roy A (1983) Family history of suicide. Archives of General Psychiatry, 40, 971-974.
80. Roy A, Ågren H, Pickar D, et al. (1986) Reduced CSF concentrations of homovanillic acid and homovanillic acid to 5-hydroxyindoleacetic acid ratios in depressed patients: relationship to suicidal behavior and dexamethasone nonsuppression. American Journal of Psychiatry, 143, 1539-1545.
81. Sacchetti E, Vita A, Guarneri L, et al. (1991) The effectiveness of fluoxetine, clomipramine, nortriptyline and desipramine in major depressives with suicidal behaviour: preliminary findings. In: Serotonin-related Psychiatric Syndromes: Clinical and Therapeutic Links (Eds GB Cassano and HS Akiskal), Royal Society of Medicine Services International Congress and Symposium Series, 165, pp. 47-53. Royal Society of Medicine Services Limited, London.
82. Salzmann C, Kochansky GE, Shader RI, et al. (1974) Chlordiazepoxide-induced hostility in a small group setting. Archives of General Psychiatry, 31, 401-405.
83. Schifano F (1994) Pharmacological strategies for preventing suicidal behaviour. CNS Drugs, 1, 16-25.
84. Schifano R, Magni G and Corfini A (1991) Antidepressivi e apparato cardiovasculare. Aspetti farmacologici e clinici. Quad Ital Psichiatr, 10, 221-244.
85. Schulsinger R, Kety S, Rosenthal D and Wonder PH (1979) A family study of suicide. In: Origin, Prevention and Treatment of Affective Disorders (Eds M Schon and E Stromberg), pp. 277-287. Academic Press, New York.
86. Stanley M and Mann JJ (1983) Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet, i, 214-216.
87. Stanley M, Virgilio J and Gershon S (1982) Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. Science, 216, 1337-1339.
88. Starkey IR and Lawson AAH (1980) Psychiatric aspect of acute poisoning with tricyclic and related antidepressants. A ten year review. Scottish Medical Journal, 25, 303-308.
89. Taiminen TJ (1993) Effect of psychopharmacotherapy on suicide risk in psychiatric inpatients. Acta Psychiatrica Scandinavica, 87, 45-47.
90. Teicher MH, Glod C and Cole JO (1990) Emergence of intense suicidal preoccupation during fluoxetine treatment. American Journal of Psychiatry, 147, 207-210.
91. Thies-Flechtner K, Seibert W, Walthar A, Greil W, Müller-Oerlinghausen B (1994) Suizide bei rezidivprophylaktisch behandelten Patienten mit affektiven Psychosen. In: Ziele und Ergebnisse der medikamentösen Prophylaxe affektiver Psychosen (Eds B Müller-Oerlinghausen and A Berghöfer), pp. 61-64. Georg Thiem, Stuttgart.
92. Träskman-Bendz L, Ailing C, Oreland L, Regnéll Göran, Vinge E and Öhman R (1992) Prediction of suicidal behavior from biologic tests. Journal of Clinical Psychopharmacology, 12, 21S-26S.
93. Träskman L, Åsberg M, Bertilsson L and Sjöstrand L (1981) Monoamine metabolites in CSF and suicidal behavior. Archives of General Psychiatry, 38, 631-636.
94. Volk J and Muller-Oerlinghausen B (1988) Quality of inter-episodic periods in patients with affective disorders under long-term lithium treatment. Pharmacopsychiatry, 21, 426-427.
95. Wagner W, Plekkempol B, Gray TE, Vlaskamp H and Essers H (1992) Review of fluvoxamine safety database. Drugs, 43 (Suppl 2), 48-52.
96. Wakelin J (1988) The role of serotonin in depression and suicide. Advances in Biological Psychiatry, 17, 70-83.